Ratings by Citi (Laura Sutcliffe)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/26/2026 | Telix Pharmaceuticals Ltd | TLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2026 | Telix Pharmaceuticals Ltd | TLX | Maintain | Buy (N/A) |
|
Details | ||
| 7/13/2026 | ResMed | RMD | Downgrade | Neutral (Buy) |
208.45 (252.83) |
21.29% | Details | |
| 7/7/2026 | Telix Pharmaceuticals Ltd | TLX | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | ResMed | RMD | New Coverage | Buy (N/A) |
271.71 (252.83) |
-6.95% | Details | |
| 9/18/2025 | Telix Pharmaceuticals Ltd | TLX | New Coverage | Buy (N/A) |
9.38 (9.51) |
1.39% | Details |
